CHICAGO & DARMSTADT, Germany--(BUSINESS WIRE)--ASCO Abstract Numbers: 2010, TPS151, TPS152 Merck Serono, a division of Merck KGaA, Darmstadt, Germany announced today that long-term follow-up data of a randomized Phase II study of two cilengitide doses in recurrent glioblastoma were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The data showed that treatment of 15 patients with the investigational integrin-inhibitor for more than six months and for up to 4.5 years did not result in any treatment-related severe adverse events (Grade 3/4). In addition, 37% of patients who received the higher dose of cilengitide (2000 mg) were still alive after one year and 22% after two years.1 The current prognosis of patients with recurrent glioblastoma is poor with median overall survival (OS) between 4-7 months and one year survival rates of approximately 20%.
